{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:12:19Z","timestamp":1761822739106},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":4482,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1992,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We examined whether the <jats:italic>N<\/jats:italic>\u2010methyl\u2010D\u2010aspartate antagonist MK\u2010801 (dizocilpine) would reverse parkinsonism or potentiate the effects of L\u2010dopa in primates treated with 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP). In contrast to its effect in rodent models, treatment with MK\u2010801 (0.1 mg\/kg) caused bradykinesia and ataxia in parkinsonian primates, but no locomotor stimulation. Coadministration of MK\u2010801 (0.1 mg\/kg) with L\u2010dopa (20 mg\/kg) induced marked dystonia accompanied by bradykinesia and ataxia. Dystonia was not induced by either treatment given alone. These findings indicate that MK\u2010801 should not be advocated as an adjunct to dopamine agonist therapy in Parkinson's disease.<\/jats:p>","DOI":"10.1002\/ana.410320118","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T12:15:39Z","timestamp":1104581739000},"page":"103-105","source":"Crossref","is-referenced-by-count":24,"title":["Dystonia induced by combined treatment with <scp>L<\/scp>\u2010dopa and MK\u2010801 in parkinsonian monkeys"],"prefix":"10.1002","volume":"32","author":[{"given":"N. M. J.","family":"Rupniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Steventon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(89)90007-6"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(90)90108-M"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01258633"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280411"},{"key":"e_1_2_1_7_2","first-page":"35","article-title":"Central sympathomimetic activity of (+)\u20105\u2010methyl\u201010,11\u2010dihydro\u20105H\u2010dibenzo(a,d)cyclohepten\u20105,10\u2010imine (MK\u2010801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties","volume":"2","author":"Clineschmidt BV","year":"1982","journal-title":"Drug Dev Res"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90007-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(90)90151-4"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90638-R"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244143"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244093"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(89)90221-9"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(05)80002-6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245739"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)92783-F"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)91252-3"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91180-O"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/349414a0"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410320118","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410320118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T18:58:57Z","timestamp":1698087537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410320118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1992,7]]}},"alternative-id":["10.1002\/ana.410320118"],"URL":"https:\/\/doi.org\/10.1002\/ana.410320118","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,7]]}}}